CRISM Therapeutics Corp (CRTX) NPV

- Add to watchlist
- Create an alert
- This stock can be held in a




8.50p
9.00p
29.00p
£3.35 million
8.50p
8.00p
6.25p
n/a
1.00p (10.53%) Previous:
1.00p
318,145
n/a
15,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2024 | 31/12/2023 |
---|---|---|
Revenue (£m) | n/a | 0.04 |
Profit before tax (£m) | (0.59) | (0.20) |
Adjusted EPS (p): | (0.01) | (1,225.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataRecent dividends paid or declared by CRISM Therapeutics Corp:
Type | Ex-div date | Payment date | Amount |
---|---|---|---|
Special | 01/06/2023 | 14/06/2023 | 1.80p |
This data is provided by Digital Look. HL accepts no responsibility for its accuracy and you should independently check data before making any investment decision.
Full dividend historyDividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Crism Therapeutics gets clearance for UK phase 2 trial
1 September 2025 14:54
-
Crism reports progress with ChemoSeed drug delivery platform
26 August 2025 11:02
-
Notice of Interim Results and IMC Presentation
12 September 2025 07:00
-
Approval for phase 2 clinical trial
1 September 2025 07:00
-
Result of AGM
26 August 2025 16:03
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.